Print
REGENERATIVE MEDICINE / STEM CELLS:
Osiris Wins Canadian Approval for World’s First Stem Cell DrugProchymal is only approved treatment for GvHD.
Osiris Therapeutics said it has received approval from Health Canada to market its stem cell therapy Prochymal for the treatment of acute graft-vs-host disease in children.
Trials and Tribulations
Express Scripts Settles Employee Theft ChargesThe weekly round-up of failed trials, missed targets, and other business mishaps. Read More.Drug Development
Vertex’s Cystic Fibrosis Considered ‘Game-Changer’Interim mid-stage data on combination therapy impresses investors. Read More.Trials and Tribulations
Blech, One-Time "King of Biotech," Pleaded Guilty to Manipulating Stock PricesThe weekly round-up of failed trials, missed targets, and other business mishaps. Read More.Business Strategy
Protalix Approval a Win for Its Manufacturing TechnologyPodcast: May 7, 2012 Read More.Trials and Tribulations
Hedge Fund Attacks Savient Over FinancialsThe weekly round-up of failed trials, missed targets, and other business mishaps. Read More.Business Strategy
AstraZeneca CEO to Step DownPoor R&D productivity and heightened generic drug competition hamper company. Read More.Trials and Tribulations
Takeda Fails to Win FDA Approval for Diabetes DrugThe weekly round-up of failed trials, missed targets, and other business mishaps. Read More.Dealmaking
Roche Decides Against Extending Offer for IlluminaIllumina remains independent, but shares fall as offer expires. Read More.Trials and Tribulations
NICE Rejects Avastin for Breast CancerThe weekly round-up of failed trials, missed targets, and other business mishaps. Read More.Drug Development
Race for All-Oral Treatment for Hep C Leaps ForwardGilead’s and Bristol-Myers Squibb’s combination therapy shows new promise. Read More.Markets
What's Ahead for Biotech Stocks Podcast: April 16, 2012 Read More.Drug Development
U.S. Should Tax Medical Services to Fund Public Health, Says IOMStudy says investing in wellness and prevention could close the healthcare gap between U.S. and other wealthy nations. Read More.Drug Development
R&D Spending for Drug Giants Drops to $49.5 Billion in 2011Industry remains among the most research-intensive. Read More.Trials and Tribulations
J&J Fined $1.1 Billion For Deceptive MarketingThe weekly roundup of failed trials, missed targets, and other business mishaps. Read More.Dealmaking
Amgen and AstraZeneca to Collaborate on Inflammation PortfolioCompanies will develop and commercialize five monoclonal antibodies. Read More.
.gif)
.png){kind=small} |
 |